Pfizer Wins Battle for Weight-Loss Drugmaker Metsera. Novo Nordisk Is the Real Winner.
1. Metsera's stock fell 15% post-Pfizer's $10 billion acquisition agreement. 2. Pfizer offers $65.60 per share, plus potential $20.65 contingent payments. 3. Novo Nordisk declined to raise bid, focusing on financial discipline. 4. Market reaction indicates investor relief as Novo opts not to compete further. 5. Pfizer aims to finalize the deal post Metsera's stockholder meeting.